Protara Therapeutics, Inc. announced the appointment of Jathin Bandari, M.D., as Chief Medical Officer. Dr. Bandari is a practicing urologic oncologist, recently serving at the University of Rochester where he specialized in both minimally invasive urologic oncology and advanced open pelvic retroperitoneal cancer surgery, and where he maintains a faculty appointment. Dr. Bandari joined Protara in April 2020 as Vice President, Head of Clinical Development, and most recently was Interim Chief Medical Officer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.8 USD | -0.36% | 0.00% | +49.33% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+49.33% | 57.65M | |
+15.55% | 121B | |
+12.66% | 107B | |
-2.53% | 24.82B | |
+1.34% | 22.48B | |
-9.86% | 18.32B | |
-42.28% | 16.33B | |
-18.92% | 15.31B | |
+6.19% | 14.08B | |
+28.83% | 11.74B |
- Stock Market
- Equities
- TARA Stock
- News Protara Therapeutics, Inc.
- Protara Therapeutics Announces Appointment of Jathin Bandari, M.D. as Chief Medical Officer